References 1 Ferlay J et al . Cancer incidence and mortality worldwide : sources , methods and major patterns in GLOBOCAN 2012 . Int J Cancer 2015 ; 136 : E359 – 86 . 2 National Cancer Intelligence Network . Stage Breakdown by CCG 2014 . London : NCIN ; 2016 . 3 Northern Ireland Cancer Registry , Queens University Belfast , Incidence by stage 2010 – 2014 . Belfast : NICR ; 2016 . 4 Alexandrov LB et al . Signatures of mutational processes in human cancer . Nature 2013 ; 500:415 – 21 . 5 Howlader N et al . SEER Cancer Statistics Review , 1975 – 2014 , based on November 2016 SEER data submission . Bethesda , MD : National Cancer Institute ; 2017 . https :// seer . cancer . gov / csr / 1975 _ 2014 / ( accessed May 2018 ). 6 Johnson DH , Schiller JH , Bunn PA Jr . Recent clinical advances in lung cancer management . J Clin Oncol 2014 ; 32:973 – 82 . 7 Reck M et al . Management of non-small-cell lung cancer : recent developments . Lancet 2013 ; 382:709 – 19 . 8 Forde PM , Ettinger DS . Targeted therapy for non-small-cell lung cancer : past , present and future . Expert Rev Anticancer Ther 2013 ; 13:745 – 8 . 9 Ettinger DS . Ten years of progress in non-small cell lung cancer . J Natl Compr Canc Netw 2012 ; 10:292 – 5 . 10 Swanton C , Govindan R . Clinical implications of genomic discoveries in lung cancer . N Engl J Med 2016 ; 374:1864 – 73 . 11 Kris MG et al . Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs . JAMA 2014 ; 311:1998 – 2006 12 Kwak EL et al . Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer . N Engl J Med 2010 ; 363:1693 – 703 . 13 Cancer Genome Atlas Research Network . Comprehensive molecular profiling of lung adenocarcinoma . Nature 2014 ; 511:543 – 50 . 14 Soda M et al . Identification of the transforming EML4-ALK fusion gene in non small cell lung cancer . Nature 2007 ; 448:561 – 6 . 15 Takeuchi K et al . Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts . Clin Cancer Res 2008 ; 14:6618 – 24 . 16 Hallberg B , Palmer RH . The role of the ALK receptor in cancer biology . Ann Oncol 2016 ; 27 ( Suppl 3 ): iii4 – iii15 . 17 Choi YL et al . A novel fusion of TPR and ALK in lung adenocarcinoma . J Thorac Oncol 2014 ; 9:563 – 6 . 18 Fang DD et al . HIP1-ALK , a novel ALK fusion variant that responds to crizotinib . J Thorac Oncol 2014 ; 9:285 – 94 . 19 Hong M et al . HIP1-ALK , a novel fusion protein identified in lung adenocarcinoma . J Thorac Oncol 2014 ; 9:419 – 22 . 20 Cui S et al . Use of capturebased next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer . Oncotarget 2017 ; 8 ( 2 ): 2771 – 80 . 21 Solomon BJ et al . First-line crizotinib versus chemotherapy in ALK-positive lung cancer . N Engl J Med 2014 ; 371:2167 – 77 . 22 Seto T . et al . CH5424802 ( RO5424802 ) for patients with ALK-rearranged advanced nonsmall-cell lung cancer ( AF-001JP study ): a single-arm , open-label , phase 1-2 study . Lancet Oncol |
2013 ; 14:590 – 8 . 23 Peters S et al . Alectinib versus crizotinib in untreated ALK-positive non – small-cell lung cancer . N Engl J Med 2017 ; 377 ( 9 ): 829 – 38 . 24 Iwama E et al Development of anaplastic lymphoma kinase ( ALK ) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer . Onco Targets Ther 2014 ; 7:375 – 85 . 25 Shaw AT , Kim DW , Nakagawa K . Crizotinib versus chemotherapy in advanced ALK-positive lung cancer . N Engl J Med 2013 ; 368:2385 – 94 . 26 Hunt J . Molecular pathology in anatomic pathology practice : a review of basic principles . Arch Pathol Lab Med 2007 ; 132 ( 2 ): 248 – 60 . 27 Babic A et al . The impact of preanalytical processing on staining quality for H & E , dual hapten , dual color in situ hybridization and fluorescent in situ hybridization assays . Methods . 2010 ; 52 ( 4 ): 287 – 300 . 28 Minca E et al . ALK status testing in nonsmall cell lung carcinoma : correlation between ultrasensitive IHC and FISH . J Mol Diagn 2013 ; 15 ( 3 ): 341 – 6 . 29 Sholl L et al . Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas . J Thorac Oncol 2013 ; 8 ( 3 ): 322 – 8 . 30 Camidge DR et al . Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer . Implications for ALK inhibitor therapy . Cancer 2013 ; 119 ( 22 ): 3968 – 75 . 31 Selinger C et al . Testing for ALK rearrangement in lung adenocarcinoma : a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization . Mod Pathol 2013 ; 26 ( 12 ): 1545 – 53 . 32 Conde E et al . Accurate identification of ALK positive lung carcinoma patients : novel FDAcleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry . PLoS One 2014 ; 9 : e107200 . 33 Ying J et al . Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma . Ann Oncol 2013 ; 24:2589 – 93 . 34 Kim H et al . Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases . Histopathology 2013 ; 62 ( 2 ): 305 – 14 . 35 Salido M et al . Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer . J Thorac Oncol 2011 ; 6 ( 1 ): 21 – 7 . 36 Yatabe Y . ALK FISH and IHC : you cannot have one without the other . J Thorac Oncol 2015 ; 10:548 – 50 . 37 Savic S et al . Screening for ALK in non-small cell lung carcinomas : 5A4 and D5F3 antibodies perform equally well , but combined use with FISH is recommended . Lung Cancer 2015 ; 89:104 – 9 . 38 Leighl NB et al . Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors : American Society of Clinical Oncology endorsement of the College of American Pathologists / International Association for the |
study of lung cancer / association for molecular pathology guideline . J Clin Oncol 2014 ; 32:3673 – 9 . 39 Cabillic F et al . Parallel FISH and immunohistochemical studies of ALK status in 3244 non-smallcell lung cancers reveal major discordances . J Thorac Oncol 2014 ; 9:295 – 306 . 40 Ilie MI et al . Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘ borderline ’ - positive rearrangements or a high copy number : a potential major issue for anti-ALK therapeutic strategies . Ann Oncol 2015 ; 26:238 – 44 . 41 Antonescu CR et al . Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement . Am J Surg Pathol 2015 ; 39:957 – 67 . 42 Roychowdhury S et al . Personalized oncology through integrative high-throughput sequencing : a pilot study . Sci Transl Med 2011 ; 3:111ra121 . 43 Frampton GM et al . Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing . Nat Biotechnol 2013 ; 31:1023 – 31 . 44 Kamps R et al . Next-generation sequencing in oncology : Genetic diagnosis , risk prediction and cancer classification . Int J Med Sci 2017 ; 18 ( 2 ): 308 . 45 Wu K et al . Next-generation sequencing for lung cancer . Future Oncol 2013 ; 9:1323 – 36 . 46 Demidova I et al . Detection of ALK rearrangements in 4002 Russian patients : The utility of different diagnostic approaches . Lung Cancer 2017 ; 103:17 – 23 . 47 Li W et al . Combinational analysis of FISH and immunohistochemistry reveals rare genomic events in ALK fusion patterns in NSCLC that responds to crizotinib treatment . J Thorac Oncol 2017 ; 12:94 – 101 . 48 Pekar-Zlotin M et al . Fluorescence in situ hybridization , immunohistochemistry , and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer . Oncologist 2015 ; 20:316 – 22 . 49 Ali SM et al . Comprehensive genomic profiling identifies a subset of crizotinibresponsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization . Oncologist 2016 ; 6:762 – 70 . 50 Pirazzoli V et al . Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1 . Cell Rep 2014 ; 7:999 – 1008 . 51 Coco S , Truini A , Vanni I . Next generation sequencing in non-small cell lung cancer : new avenues toward the personalized medicine . Curr Drug Targets 2015 ; 16:47 – 59 . 52 Oxnard GR , Arcila ME , Sima CS . Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer : distinct natural history of patients with tumors harboring the T790M mutation . Clin Cancer Res 2011 ; 17:1616 – 22 . 53 Choi YL , Soda M , Yamashita Y . EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors . N Engl J Med 2010 ; 363:1734 – 9 . 54 Doebele RC , Pilling AB , Aisner DL . Mechanisms of resistance to crizotinib in patients with ALK |
gene rearranged non-small cell lung cancer . Clin Cancer Res 2012 ; 18:1472 – 82 . 55 Sasaki T ., Koivunen J ., Ogino A . A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors . Cancer Res 2011 ; 71:6051 – 60 . 56 Ettinger DS et al . Non-small cell lung cancer , Version 6.2015 . J Natl Compr Canc Network 2015 ; 13 ( 5 ): 515 – 24 . 57 Lee CK et al . Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival : A meta-analysis . J Natl Cancer Inst 2013 ; 105 : 595 – 605 . 58 Lindeman N et al . Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors . J Mol Diagn 2018 ; 20:129 – 59 . 59 Bulman W , Saqi A , Powell CA . Acquisition and processing of endobronchial ultrasound-guided transbronchial needle aspiration specimens in the era of targeted lung cancer chemotherapy . Am J Respir Crit Care Med 2012 ; 185:606 – 11 . 60 Jurado J et al . The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma . Ann Thorac Surg 2013 ; 96 : 1196 – 202 . 61 Sequist LV et al . Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice . Ann Oncol 2011 ; 22:2616 – 24 . 62 Li T et al . Genotyping and genomic profiling of non-smallcell lung cancer : Implications for current and future therapies . J Clin Oncol 2013 ; 31:1039 – 49 . 63 Endris V et al . Molecular diagnostic profiling of lung cancer specimens with a semiconductorbased massive parallel sequencing approach : feasibility , costs , and performance compared with conventional sequencing . J Mol Diagn 2013 ; 15:765e775 . 64 Sorber L et al . Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients . Lung Cancer 2017 ; 107:100 – 7 . 65 Travis WD et al . Diagnosis of lung adenocarcinoma in resected specimens : implications of the 2011 International Association for the Study of Lung Cancer / American Thoracic Society / European Respiratory Society classification . Arch Pathol Lab Med 2013 ; 137:685 – 705 . 66 National Lung Cancer Audit Report 2012 [ Internet ]. 2012 . www . hqip . org . uk / assets / NCAPOP- Library / NCAPOP-2012-13 / Lung-Cancer-National-Audit- Report-pub-2012 . pdf ( accessed May 2018 ). 67 Rosen S . World Market for Cancer Diagnostics , 5th Edition . 2013 . 68 Travis WD et al . International Association for the Study of Lung Cancer / American Thoracic Society / European Respiratory Society : International multidisciplinary classification of lung adenocarcinoma : executive summary . Proc Am Thorac Soc 2011 ; 8:381 – 5 . 69 Xu Set al . Circulating tumor DNA identified by targeted sequencing in advancedstage non-small cell lung cancer patients . Cancer Lett 2016 ; 370:324 – 31 . 70 Ross K et al . The potential diagnostic power of circulating tumor cell analysis for |
non-small-cell lung cancer . Expert Rev Mol Diagn . 2015 ; 15:1605 – 29 . 71 Lanman RB et al . Analytical and clinical validation of a digital sequencing panel for quantitative , highly accurate evaluation of cellfree circulating tumor DNA . PLOS One 2015 ; 10 ( 10 ): e0140712 . 72 Schwaederle M et al . Detection rate of actionable mutations in diverse cancers using a biopsy-free ( blood ) circulating tumor cell DNA assay . Oncotarget 2016 ; 7 ( 9 ): 9707 – 17 . 73 Massard C et al . Highthroughput genomics and clinical outcome in hard-to-treat advanced cancers : Results of the MOSCATO 01 Trial . Cancer Discov . 2017 ; 7:586 – 95 . 74 Dalton WB et al . Personalized medicine in the oncology clinic : Implementation and outcomes of the Johns Hopkins Molecular Tumor Board . JCO Precision Oncology 2017 ; 31 May [ Epub ahead of print ]. 75 Rogers T-M et al . Multiplexed transcriptome analysis to detect ALK , ROS1 and RET rearrangements in lung cancer . Sci Rep 2017 ; 7:42259 . 76 Letovanec I et al . Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients : Results from the ETOP Lungscape Project . J Thorac Oncol 2018 ; 13 ( 3 ): 413 – 25 . |
150 |
||||
HHE 2018 | hospitalhealthcare . com |